Anumana has entered into a partnership with digital health company InfoBionic.Ai to advance artificial intelligence (AI)-based remote cardiac telemetry technology for the early detection of cardiac diseases.
The partnership will combine Anumana’s ECG-AI technology and InfoBionic.Ai’s MoMe ARC platform. This will enable the parties to develop and commercialise next-generation remote cardiac care solutions as part of their joint research collaboration agreement.
Anumana, which focuses on AI-driven health technology, is a portfolio company of nference. The firm has developed and validated ECG-AI algorithms in collaboration with Mayo Clinic.
Its partnership with InfoBionic.Ai will aim to improve the capability of the MoMe ARC Platform to detect and address cardiac diseases earlier during remote patient monitoring.
Anumana CEO Maulik Nanavaty said: “This collaboration marks an important step in Anumana’s mission to revolutionise cardiac care by enhancing the power of ECG with AI.
“Since the founding of Anumana, our vision has been to elevate the utility of ECG with AI across all the settings in which ECGs are used.”
Both Anumana and InfoBionic.Ai are portfolio companies of Mayo Clinic. They will maintain their close collaboration with the nonprofit American academic medical centre under this research agreement.
Under the agreement, both partners will collaborate to develop and integrate Anumana’s ECG-AI algorithms, beginning with the ECG-AI LEF algorithm, into InfoBionic.Ai’s continuous and remote cardiac monitoring platform.
The companies will jointly validate the clinical effectiveness of the integrated solution and pursue regulatory clearance to launch the technology to market.
The ECG-AI LEF algorithm received the US Food and Drug Administration (FDA) clearance in September 2023 and is presently undergoing review in Europe.
The MoMe ARC platform is said to be the first and only continuous six-lead FDA-cleared solution that incorporates advanced AI analysis and native business intelligence.
It includes a 4-in-1 Gateway device that seamlessly switches between 2-day Holter, extended Holter, Event, and MCT modes remotely.
InfoBionic.Ai board director Peter Noseworthy said: “By combining InfoBionic.Ai’s remote monitoring solutions with Anumana’s innovative ECG-AI algorithms, including the FDA-cleared algorithm for detecting low ejection fraction (LEF), we aim to equip healthcare providers with the latest cutting-edge tools to detect underlying cardiac conditions earlier, enabling timely intervention and personalised care.”
Last month, InfoBionic.Ai joined forces with HBox.ai to develop a cardiovascular care solution. The collaboration involves the integration of HBox.ai’s virtual care model with InfoBionic.Ai’s advanced cardiac telemetry.
